Primary Dysmenorrhea
Investigational use for primary dysmenorrhea refractory to NSAIDs and hormonal contraception; small case series.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for primary dysmenorrhea. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). One single-arm pilot describes pain reduction; there are no randomized controlled trials. Evidence-based first-line therapy is non-steroidal anti-inflammatory drugs (NSAIDs — ibuprofen, naproxen) started at first symptom or 1 to 2 days before expected menses, with combined oral contraceptives or levonorgestrel IUS for refractory cases or contraception needs. Heat application, regular exercise, and dietary measures are adjuncts. Secondary dysmenorrhea (endometriosis, fibroids, adenomyosis, pelvic inflammatory disease) requires identification and treatment of the underlying cause.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the abdomen and sacrum for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Worsening of cramping in the first 24 hours
- Small permanent scars at bite sites
- Missed diagnosis of secondary dysmenorrhea (endometriosis, fibroids, adenomyosis) if not investigated
- Delay or replacement of NSAIDs or hormonal therapy
- Quién no debería considerar esto
- Patients who are pregnant or might be pregnant
- Patients with active pelvic infection (PID, tubo-ovarian abscess)
- Patients with secondary dysmenorrhea from structural pathology (endometriosis, fibroids) without specialty evaluation
- Patients with severe acute pain different from typical menstrual cramping
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients who have not tried evidence-based NSAIDs or hormonal options
- Qué preguntar a su clínico
- Has my dysmenorrhea been classified as primary or secondary?
- Have I tried scheduled NSAIDs (ibuprofen 400 to 800 mg every 6 to 8 hours) started before menses?
- Am I a candidate for combined oral contraceptives or levonorgestrel IUS?
- Have I been screened for endometriosis (severe symptoms refractory to standard therapy may warrant evaluation)?
- Have I tried heat application, regular exercise, and stress reduction?
- Where exactly will leeches be placed — NEVER intravaginally?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Cuándo buscar atención urgente
- Sudden severe pelvic pain with nausea, vomiting, fever, or fainting (possible ovarian torsion, ruptured cyst, or ectopic — call 911 or go to ER)
- Heavy vaginal bleeding with positive pregnancy test (possible ectopic — emergency)
- Severe pelvic pain with high fever and chills (possible PID)
- Severe pain refractory to NSAIDs that is dramatically worse than usual menstrual cramps
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Qué NO significa esto
- This is not FDA-cleared for primary dysmenorrhea.
- A single small uncontrolled pilot does NOT establish efficacy versus NSAIDs or hormonal therapy.
- Mechanism rationale (prostaglandin modulation) does NOT establish clinical efficacy.
- Leech therapy is NEVER intravaginal — that placement is contraindicated.
- Leech therapy is not a substitute for NSAIDs, hormonal therapy, or specialty evaluation for secondary dysmenorrhea.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- gynecologic
- ICD-10
- N94.4, N94.5, N94.6
- Safety tier
- low
Evidence Summary
No controlled clinical trial or published pilot of leech therapy for dysmenorrhea exists; any use is investigational and mechanistic only, with a proposed but unproven mechanism involving uterine prostaglandin modulation and local decongestion. Standard management (NSAIDs taken in the perimenstrual window, combined oral contraceptives, LNG-IUS) remains first-line. Leech therapy would only be reserved for refractory cases or those declining hormonal therapy, as an unproven option. Secondary dysmenorrhea (endometriosis, fibroids, adenomyosis) requires identification and treatment of the underlying pathology.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Bahmani M et al. (2014), n=20
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Pregnancy
- Active pelvic infection
- Secondary dysmenorrhea with structural pathology (treat underlying)
Related Conditions
Lactational Mastitis (Non-Suppurative)
Investigational adjunctive use for non-suppurative lactational mastitis; case-series evidence for resolution of induration and reduced antibiotic days.
Endometriosis-Related Pelvic Pain
Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.
Chronic Pelvic Pain Syndrome (Non-Specific)
Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.
Premenstrual Syndrome (Investigational)
Investigational adjunct for moderate PMS refractory to conventional therapy; small case series only; SSRI and combined hormonal contraception remain primary.